Research Antibodies and Reagents Market Worth $14.56 Billion by 2025 – Exclusive Report by Meticulous Research – GlobeNewswire

London, Nov. 25, 2019 (GLOBE NEWSWIRE) -- According to a new market research report Research Antibodies and Reagents Market by Product (Reagent [Sample Preparation (Media, Probe, Buffer), Antibody Production Reagent], Antibody [Type, Source, Research Area]), Technology (Western Blot, ELISA), Application, End-User - Global Forecast to 2025, published by Meticulous Research, the research antibodies and reagents market is expected to grow at a CAGR of 6% from 2019 to 2025 to reach $14.56 billion by 2025.

Research antibodies act as a vital tool in laboratory techniques that are conducted for research purpose. Due to their high specificity and sensitivity, antibodies and associated reagents make an exquisite tool aiding in the detection of molecules and its analysis, which enables the researchers to draw conclusions related to drug target, disease occurrence, and immune system pathways. The rising proteomics and genomic research studies, increase in the funding for research activities, and growing industry-academia collaborations are the key factors driving steady growth in the global research antibodies and reagents market.

Request Sample Report:https://www.meticulousresearch.com/request-sample-report/cp_id=5055

In recent years, the funding for healthcare research projects has increased significantly. According to the Research America, investment in medical and health research and development by the U.S. has increased by 18.1% between 2014 and 2017. In 2017, total expenditure on medical and health R&D in the U.S. was $182.3 billion. Industry, including pharmaceutical, medical technology, biotechnology and health IT companies, accounted for the largest share of the U.S. investment in medical and health R&D over the reporting period. Similarly, in Europe, according to European Union (EU), Horizon 2020 program was launched in 2016, with an investment of $88.5 billion (80 billion); of which around 10% (~$9 billion) was utilized for healthcare sector. The initiative was aimed at developing and supporting personalized medicine projects. Also, during the period of 2014-2016, the European Commission invested more than $2.7 billion (2.4 billion) in projects that supported innovation in personalized medicine. Therefore, such increase in funding has led to rise in research activities in pharmaceutical and biotechnology industries, thereby boosting the demand for research antibodies and reagents.

The research antibodies and reagents market study presents historical market data in terms of value (2017 and 2018), estimated current data (2019), and forecasts for 2025 by product, technology, application, end user, and geography. The study also evaluates industry competitors and analyzes their market share at the global and regional levels.

Based on product, reagents segment is estimated to account for the largest share of the overall research antibodies and reagents market in 2019 and is slated to grow at the fastest CAGR during the forecast period. The large share of this segment is attributed to recurrent use of reagents in many research assays and techniques and increasing developments in research reagents.

Based on technology, western blotting segment is estimated to account for the largest share of the overall research antibodies and reagents market in 2019. This is mainly attributed to increasing focus on initiating developments in diagnosis and therapy procedures and rising research funding for biomarker discovery and antibody & cell-based products. On the other hand, Enzyme-linked Immunosorbent Assay (ELISA) is slated to grow at the fastest CAGR during the forecast period due to increasing use of ELISA technology for screening of active ingredients and validation of obtained hits in drug discovery.

Based on application, proteomics segment is estimated to hold the largest share of the overall research antibodies and reagents market in 2019. This is mainly attributed to the increase in search for ideal candidates for use as anti-cancer drugs, need for designing more effective drugs, assessment of drug efficacy and patient response, and development of antibodies especially monoclonal antibodies. Growing use of proteomic technologies in development of target-based therapies also supports the large share and growth in this market.

Based on end user, pharmaceutical and biotechnology companies segment is estimated to hold the largest share of the overall research antibodies and reagents market in 2019, due to high adoption of research antibodies & reagents in proteomics research and drug discovery and development programs. Rising focus of industry players on developing innovative therapeutics for chronic diseases is contributing to the growth of this market. On the other hand, the demand for research antibodies from contract research organizations (CROs) is slated to grow fastest during the forecast period, mainly due to increase in outsourcing activities by pharmaceutical industries to CROs.

The report also includes extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 4 years (2016-2019). The research antibodies and reagents market has witnessed number of partnerships & agreements in the recent years. For instance, in January 2018, Abcam plc (U.K.) entered into an agreement with Roche to facilitate licensing of product portfolio of Spring Bioscience Corporation to Abcam for research use only (RUO) applications, which includes recombinant antibodies. Similarly, in October 2017, Bio-Techne Corporation (U.S.) entered into an agreement with Joint Consortia Framework for the development of research antibodies & antibody-based reagents. Similarly, in January 2018, Illumina, Inc. (U.S.) launched iSeq 100 sequencing system, which offers exceptional data accuracy, at a low capital cost.

The global research antibodies and reagents market is highly fragmented with the presence of key players, such as, Abcam plc (U.K.), Merck KGaA (Germany), Cell Signaling Technology, Inc. (U.S.),GE Healthcare (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann La-Roche Ltd (Switzerland), Rockland Immunochemicals Inc. (U.S.), Johnson & Johnson (U.S.), Agilent Technologies, Inc. (U.S.), Eli Lily and Company (U.S.), Becton Dickinson and Company (U.S.), Danaher Corporation (U.S.), PerkinElmer, Inc. (U.S.), GenScript Biotech Corporation (U.S.), Lonza (Switzerland), Bio-Techne Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Teva Pharmaceutical Industries Limited (Israel), Santa Cruz Biotechnology, Inc. (U.S.), and BioLegend, Inc.(U.S.) among others.

Browse key industry insights spread across 280 pages with 256 market data tables & 61 figures & charts from the report:https://www.meticulousresearch.com/product/research-antibodies-reagents-market-5055/

Scope of the Report:

Research Antibodies and Reagents Market, by Product

Research Antibodies and Reagents Market, by Technology

Research Antibodies and Reagents Market, by Application

Research Antibodies and Reagents Market, by End User

Research Antibodies and Reagents Market, by Geography

DownloadFree Sample Report Now @https://www.meticulousresearch.com/download-sample-report/cp_id=5055

Related Reports:Immunoassay Market by Product (Kits and Reagents, Analyzers, Software), Platform (Chemiluminescence, Radioimmunoassays) Application (Infectious Diseases, Cardiology), End-User (Hospitals, Academic Laboratories), and Geography - Global Forecast to 2025, read more:https://www.meticulousresearch.com/product/immunoassay-market-4982/

Cell Culture Market by Product [Consumables (Media, Reagents, Sera, FBS, Antibiotics, Growth Factor, Buffer), Equipment (Bioreactor, Centrifuge)], Application (Biopharmaceutical, Cancer, Stem Cell), and End User (Pharma, Research)- Global Forecast to 2024, read more:https://www.meticulousresearch.com/product/cell-culture-market/

About Meticulous Research

The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze and present the critical market data with great attention to details.

Meticulous Research was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, with the help of its unique research methodologies, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa regions.

With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.

Follow this link:
Research Antibodies and Reagents Market Worth $14.56 Billion by 2025 - Exclusive Report by Meticulous Research - GlobeNewswire

Immune-Onc Therapeutics Prepares for its Next Phase of Growth with New Leadership Appointments and Key Board Member Additions – Business Wire

PALO ALTO, Calif.--(BUSINESS WIRE)--Immune-Onc Therapeutics, Inc. (Immune-Onc), a privately held cancer immunotherapy company, announced today the addition of several industry veterans to its executive team and advisory boards and the promotion of An Song, Ph.D. to Chief Scientific Officer from Senior Vice President of Development Sciences. Dr. Paul Woodard joins Immune-Onc from Bellicum Pharmaceuticals, Inc. where he most recently served as Senior Vice President, Clinical and Medical Affairs.

We are thrilled to add such seasoned and strategic individuals to the executive and advisory teams guiding Immune-Onc through its next phase of growth as a clinical stage company, said Charlene Liao, Ph.D., Co-founder and Chief Executive Officer of Immune-Onc. As our Chief Medical Officer, Paul brings the right combination of deep expertise in oncology paired with proven strategic leadership and experience building teams and functions in a startup environment. The appointment of An to Chief Scientific Officer is a reflection of the contributions she has already made to the company in her current role and a recognition of the value that her experience will bring in guiding the translation of our science into development.

I cant imagine a more exciting time to join Immune-Onc, said Dr. Woodard. I was first drawn to the novel science underlying the portfolio. As I learned more about Immune-Onc and their authentic passion for improving patient lives, it became clear to me that this was a company that I wanted to contribute to in a meaningful way with the goal of bringing much needed new treatment options to people with hard-to-treat cancers like acute myeloid leukemia.

About Paul Woodard, M.D.

As Chief Medical Officer, Dr. Woodard will be responsible for clinical leadership and medical oversight of the Immune-Onc portfolio. These activities will include review and input of IND submissions, clinical protocol development and medical oversight of Immune-Onc trials, and oversight of internal and external clinical development, biometrics, safety, and regulatory functions and compliance.

Dr. Woodard has an extensive hematology and oncology background gained in academia and industry. His academic experience focused on pediatric hematopoietic stem cell transplantation and hematologic disorders at world-renowned institutions, including St. Jude Childrens Research Hospital, University of California, San Francisco, and Childrens Hospital, Los Angeles. In addition to patient care, at St. Jude, Dr. Woodard was responsible for Phase 1/2 trials in pediatric hematopoietic stem cell transplantation for malignant and non-malignant disorders.

Prior to joining Immune-Onc, Dr. Woodard worked on a wide range of drug development projects in solid tumors, hematologic malignancies, and non-malignant hematologic disorders. At Exelixis, Dr. Woodard worked on small molecule tyrosine kinase inhibitors for solid tumors. At Amgen, Dr. Woodard was the global development leader for Nplate (romiplostim) in immune thrombocytopenia and myelodysplastic syndromes. At Genentech, Dr. Woodard was the global development team leader for Tecentriq (atezolizumab) in hematologic malignancies and was an integral team member for the development of Tecentriq combinations in solid tumors (including triple negative breast cancer) and hematologic malignancies. At Bellicum, Dr. Woodard was the Senior Vice President of Clinical and Medical Affairs, with oversight of the companys cellular therapy portfolio and clinical trials in hematologic malignancies and solid tumors.

Dr. Woodard earned his medical degree at the University of North Carolina and completed his residency at the University of Virginia and fellowships in pediatric hematology-oncology at the University of North Carolina and in pediatric blood and marrow transplantation at the University of Minnesota.

About An Song, Ph.D.

Dr. Song joined Immune-Onc in July 2018 as Senior Vice President of Development Sciences. In the newly created role of Chief Scientific Officer, Dr. Song will have overall accountability for translational development of Immune-Oncs portfolio and strategic oversight of research and antibody engineering.

Dr. Song is a translational scientist with 22 years of experience across basic research and drug development in oncology, autoimmunity, metabolic, infectious, and neurodegenerative diseases. Dr. Song joins Immune-Onc from Genentech where, as a Senior Director in BioAnalytical Sciences, she led the Assay Development and Technology group for the companys large molecule portfolio globally and was a member of numerous scientific review bodies within the Genentech Research and Early Development (gRED) organization. During her 16-year tenure at Genentech, Dr. Song contributed to, and oversaw 40+ IND/CTA and BLA/MAA regulatory filings for products including Rituxan, Avastin, Herceptin, Lucentis, Kadcyla and Tecentriq. In addition, Dr. Song played a significant role in the development and approval of Ocrevus.

Dr. Song received her Ph.D. in Biochemistry & Molecular Biology from Indiana University and completed a postdoctoral fellowship in immunology, followed by a faculty position as Assistant Professor (Research) at Stanford University. As an active member of the American Association of Pharmaceutical Scientists (AAPS), Dr. Song has served as an executive member of the Biotech Section and chair of the Therapeutic Product Immunogenicity (TPI) Focus Group/Community.

BOARD APPOINTMENTS

In addition, Immune-Onc bolstered its cadre of advisors with the appointment of Zhengbin (Bing) Yao, Ph.D. to its Board of Directors and Gregory Cosma, Ph.D. to its Scientific Advisory Board. Both Bing and Greg bring significant experience in helping early-stage companies navigate the complexity of drug development, commented Dr. Liao. Bing and Gregs perspectives are invaluable in supporting Immune-Onc in our mission to deliver transformative therapies to cancer patients.

About Zhengbin (Bing) Yao, Ph.D.

Dr. Yao has more than 20 years of experience in the biopharmaceutical industry, with a proven track record of successfully leading the discovery and development of multiple biotherapeutics. Dr. Yao is currently Chairman of the Board and CEO of Viela Bio. Prior to this role, he was Senior Vice President, Head of Respiratory, Inflammation and Autoimmune iMED at MedImmune/AstraZeneca. During his tenure at MedImmune, he played key leadership roles in the development and approval of three novel biologics for autoimmune, respiratory, and immune-oncology indications. Previously, Dr. Yao also served as Senior Vice President, Head of Immuno-Oncology Franchise, AstraZeneca, as well as CEO for WuXi-MedImmune Joint Venture. Dr. Yao joined MedImmune in 2010 from Genentech, where he was the Head of Project Team Leaders for Immunology, Infectious Diseases, Neuroscience, and Metabolic Disease. He was Vice President and Head of Research for Tanox, before the company was acquired by Genentech in 2007. Dr. Yao also held several positions of increasing responsibility at Aventis and Amgen and currently serves on the Board of Directors for NexImmune. Dr. Yao received his Ph.D. in Microbiology and Immunology from the University of Iowa, followed by postdoctoral work at Immunex.

About Gregory Cosma, Ph.D.

As a former executive at Genentech and Bristol-Myers Squibb, Dr. Cosma has a long track record of success leading companies in translating science into approved therapies. As Vice President of Research and Early Development at Genentech from 2010-2019, Dr. Cosma led the Safety Assessment organization comprising Toxicology, Pathology, Product Quality and Occupational Toxicology and Nonclinical Operations. He also chaired the Genentech Development Review Committee (DRC), overseeing nonclinical development of the Genentech pipeline from Research to First-in-Human studies. While at Bristol-Myers Squibb from 2003-2010, Dr. Cosma held roles as the Executive Director for Drug Safety Evaluation and as the Therapeutic Area Head for Metabolic Diseases. Prior to these roles, Dr. Cosma was a Research Fellow at Pharmacia-Pfizer and an assistant professor in the College of Veterinary Medicine and Biomedical Sciences at Colorado State University. Dr. Cosma earned his doctorate in Pharmacology/Toxicology at the University of Kansas.

ABOUT IMMUNE-ONC THERAPEUTICS, INC.

Immune-Onc Therapeutics, Inc. (Immune-Onc) is a privately held cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients. The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment. Immune-Onc has a promising pipeline built upon strategic collaborations and cutting-edge research from The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center. Its lead program, an antibody targeting LILRB4, is being developed to treat acute myeloid leukemia and other cancers. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies. For more information, please visit http://www.immune-onc.com.

Follow this link:
Immune-Onc Therapeutics Prepares for its Next Phase of Growth with New Leadership Appointments and Key Board Member Additions - Business Wire

Breakthrough Discovery In Plants DNA May Lead To Slowing Aging Process In Humans – CBS Pittsburgh

(CNN) Science has identified in the plant kingdom the missing link of cellular immortality between human and single-celled animals,according to a new study led by scientists from Arizona State University and Texas A&M University.

This is the first time that we have identified the detailed structure of the telomerase component from plants, said co-author Dr. Julian Chen, a professor of biochemistry at Arizona State University. The study was published Monday in the Proceedings of the National Academy of Sciences journal.

Telomerase is the enzyme that creates the DNA of telomeres, the compound structures located at the tips of our chromosomes. Telomeres protect our cells from aging as they multiply.

So in terms of fundamental research, this is a really big breakthrough because now, finally, we have a way to study telomerase in plants and to understand how different or similar they are from animals, Chen said.

READ: Two Kids Who Died After Minivan Crashed Into Canal Identified

Could the discovery possibly lead to humans one day living as long as the fabled Methuselah tree, a bristlecone pine species that can live over 5,000 years? Maybe one day.

This is really basic research. The application to humans is really a long way away, Chen said.

In the meantime, however, experts likeUniversity of California at San Franciscos Elizabeth Blackburnare bullish. Blackburn won the2009 Nobel Prize in Physiology or Medicine along withJohns Hopkins Carol GreiderandHarvards Jack Szostak for their discoveries on telomeres and telomerase.

Excitingly, this paper reports how plants fill in the missing links of telomerase RNAs eventful evolutionary history from our simplest forebears, Blackburn said. This fundamental new understanding may pave the way to new routes to optimizing telomere maintenance for human health.

Think of telomeres as the plastic caps on the ends of your shoelaces. High levels of telomerase keep those telomeres long, thus allowing them to continue to protect our cells from damage as they divide.

Most of the cells in our body have very low levels of telomerase, and thus age as they divide (picture the shoelace tips wearing away until they are gone). Aging cells equal an aging body, with cells no longer functioning normally.

However, when the cells ends are protected by telomeres, only a piece of the telomere, or cap, is lost as the cell divides,and the important DNA is left undamaged. Considering a typical cell divides about 50 to 70 times, having no protective cap could lead to chromosome instability or cells that stop dividing.

In humans, for example, egg, sperm and stem cell chromosomes contain high levels of telomerase, and so can continue to divide over and over and avoid rapid aging.

Yet even telomeres do not have eternal life. Each time a cell replicates, about 20 base pairs are lost from the telomere, or shoelace cap. We can lose even more 50 to 100 base pairs per cell division when our bodies are in oxidative stress.

We put our bodies into oxidative stress by smoking, eating a poor diet, stress and other harmful lifestyle behaviors. Between normal wear and tear and the oxidative stress of our lifestyles, even long telomeres are worn away.

But if science could harness the secret of the telomerase enzyme, its possible that we could prolong the life of telomeres, slowing the aging process.

We might be able to reversediseases in which telomeres are shortened, such as pulmonary fibrosis.

And heres another key benefit to unraveling this mystery: Cancer cells contain high levels of telomerase, allowing them to continue replicating themselves until they form tumors.

Switching off telomerase activity in cancer cells would shorten their telomeres, whittling them down to a nub called a critical length, which then triggers programmed cell death.

The ultimate goal: stopping cancer cold.

When Blackburn, Greider and Szostak won the Nobel Prize in 2009, it was for their groundbreaking discoveries on telomeres and telomerase. They extracted telomere DNA from a single-celled organism in pond scum, showed how it protected chromosomes in yeast, and identified and named the enzyme telomerase that builds the DNA of telomeres and extends their lives.

Since then, telomerases have been found to exist almost universally across species, but in complicated ways.

This enzyme action is similar from the simplest organisms to humans, Blackburn said. Yet, the telomerase RNA part of telomerase has long presented a mystery because it is surprisingly different between different evolutionary branches of life.

Each species has unique elements to their telomere RNA, and not all appear to protect against aging. For example, some species with longer telomeres have shorter life spans than those with shorter telomeres.

Scientists continue to explore the role of telomeres and the enzyme telomerase in aging, and now believe that they may only be one part of the aging process, at least in animals.

If cells have telomerase, they will live longer, but these cells are just part of your body, Chen said. Whether it can delay the entire individuals aging or increase their life span, thats a different story.

Now science has an entirely new kingdom of telomerase to dissect: Plantae, consisting of more than 2,500 species.

Maybe telomerase activity is different in plants than in animals, Chen said. We know that some of the core is similar, but you might have some additional features that plants acquire to be plant-specific.

Were hoping to learn something from their regulation, mechanisms or structures that can apply to human telomerase, Chen said. So in terms of basic research, this is really exciting because its a brand new kingdom that we can explore as to how telomeres do their jobs in plants.

The-CNN-Wire & 2019 Cable News Network, Inc., a WarnerMedia Company. All rights reserved.

Read more here:
Breakthrough Discovery In Plants DNA May Lead To Slowing Aging Process In Humans - CBS Pittsburgh

Missing Link To Longevity Discovered In The Plant Kingdom – Texas A&M University

lead researcher Dorothy Shippen, Ph.D., (left), graduate student Jiarui Song, first author (center) and postdoctoral fellow Claudia Castillo-Gonzlez, second author (right).

Texas A&M AgriLife

A breakthrough discovery by Texas A&M University and Arizona State University professors could provide a key component in understanding the human aging process and even aid in the battle against cancer.

Dorothy Shippen, Ph.D., is a University Distinguished Professor and Regents Fellow in Texas A&MsDepartment of Biochemistry and Biophysicsand withTexas A&M AgriLife Research, College Station.

Shippen co-led a study with Julian Chen, Ph.D., professor of biochemistry, Arizona State Universitys School of Molecular Sciences. First author, Jiarui Song, is a graduate student with Shippen.

Their study, The conserved structure of plant telomerase RNA provides the missing link for an evolutionary pathway from ciliates to humans, is being published in the Proceedings of the National Academy of Sciences.

Our discovery of this key component of the telomerase enzyme in the plant kingdom provides an evolutionary bridge, and a novel path forward, for understanding how humans keep their DNA safe and enable cells to divide indefinitely, Shippen said.

Moreover, since plants often evolve interesting solutions to fundamental biological problems, some of the lessons we learn from plant telomerases may provide new ways for addressing stem cell disease and cancer.

We found a core component of the telomerase enzyme that had been missing all these years, Shippen said. And by finding this component in plants, we not only learn new lessons about how telomerase evolved, but we also open the door to learn new things about the human enzyme.

Back in 2001, Shippen published a paper outlining the discovery of the catalytic subunit of the telomerase enzyme from plants. The catalytic component is one of two absolutely critical parts of the enzyme, and it is now very well understood.

However, the second component, the RNA subunit, that provides the enzyme with information about what to do with chromosome ends, was missing.

Our new discovery is the RNA subunit of telomerase from the plant kingdom. In the plant telomerase RNA, we can now see the signatures for the human telomerase and telomerase from simple organisms like bakers yeast and the microbes in pond scum.

The missing piece always was this subunit. Now that we have found the correct one, its opened up a lot of interesting insights.

Plants have different, innovative solutions to so many biological challenges, and insight into these may provide important clues on how human telomerase is regulated, she said.

We can study the telomerase enzyme more deeply and see so much more now, and it can help us understand how the human enzyme is going to work. It really is this missing middle ground.

In the 1930s, Barbara McClintockwas studying the behavior of chromosomes in maize and was one of the first scientists to appreciate the importance of telomeres.The Shippen Labin the 1990s followed up on the pioneering work of McClintock in model plant systems and discovered the telomerase enzyme, which is required for maintaining these structures on the ends of chromosomes.

Shippens longtime studies on telomerase, which play an essential role in chromosome stability and cell proliferation capacity, has led her to be considered the worlds expert in plant telomere research.

The telomere is like a biological clock. There is a certain amount of telomeric DNA at the end of chromosomes. As cells divide, they lose part of this DNA.

She has likened telomeres to the plastic tip on the end of a shoelace they form a protective seal on the ends of chromosomes in plants and animals. Like the plastic tip that wears out, allowing the shoelace to fray and become hard to use, so does the telomere break down in most cells in the human body over time.

The telomerase enzyme is capable of replenishing the lost DNA at chromosome ends and it is available in cells that are immortal, Shippen said. Its active in the stem cells, but not active in other places of the body normally.

Theres a whole connection between immortality and telomerase that needs to be studied.

Why is telomerase only active in stem cells, turned off in other cells and why does it get reactivated in cancer cells? Shippen said. Weve learned a lot about the human telomerase from pond scum, but plants can provide still more clues because their growth and development is so plastic. If you cut a flower from a plant growing in the garden, it will grow another flower. But if you cut off the tip of your finger, you wont be growing a new one.

Its a big mystery.

But Shippen said the plant telomerase is still very similar to the human telomerase.

It is remarkable that even in plants, telomerase is active only in cells that need to divide many times.

She expects that what is learned in the plant system will ultimately be translatable and have significant impact in human medicine.

Continue reading here:
Missing Link To Longevity Discovered In The Plant Kingdom - Texas A&M University

Multiple Doses of Stem Cells Show Potential in Treating Severe Asthma – PR Web

Inflammatory and remodeling processes and immunosuppressive effects in house dust mite (HDM)-induced allergic asthma.

DURHAM, N.C. (PRWEB) November 20, 2019

A study released today in STEM CELLS Translational Medicine (SCTM) describes how multiple doses of a type of stem cell called mesenchymal stromal cells (MSCs) might offer a new way to treat people suffering from severe asthma.

An asthma attack is triggered by allergens entering the lungs and causing swelling of the airways. This sets off a domino effect that results in narrowing of the airways from the nose and mouth to the lungs. The most severe cases can lead to death. According to the Centers for Disease Control and Prevention, one in 13 people have asthma. There is no cure, but it can be managed in most cases with proper prevention and treatment.

The study in SCTM, conducted by researchers at the Federal University of Rio de Janeiro and the National Institute of Science and Technology for Regenerative Medicine, focused on a new treatment for asthma brought on by house dust mites (HDMs). Some estimate that these common microscopic creatures are the culprit behind nearly 85 percent of all asthma attacks.

Patricia Rieken Macedo Rocco, M.D., Ph.D., was lead investigator on the study. Previous experiments tell us that a single dose of adipose tissue-derived MSCs reduced lung inflammation in asthma brought on by HDMs, but it was unable to reverse lung remodeling, she said. We wanted to see how multiple doses of MSCs might perform.

Earlier studies using bone marrow-derived MSCs also demonstrated therapeutic effects in HDM-induced allergic asthma, but the availability of these cells is limited due to the invasive procedure needed to harvest the cells. We opted for MSCs collected from human adipose tissue instead, as they can be easily obtained by liposuction, Dr. Rocco explained. Furthermore, adipose tissue is estimated to contain a greater number of MSCs compared to bone marrow, and these cells appear to be expandable to a higher number of passages, thus providing attractive advantages for use in a multiple-dose regimen.

For their study, the team used a mouse model that had been developed to be sensitive to HDMs. One group of animals received two intravenous doses of MSCs (105 cells/day) beginning 24 hours after being exposed to the mites; a second group received three doses; and a third group was administered dexamethasone, a steroid often used to treat experimental asthma. A control group was given saline only.

After seven days, the animals treated with the two and three doses of MSCs showed reduced lung inflammation and remodeling, improved lung function and T-cell immunosuppression, with the three-dose regimen proving the most effective.

MSC-induced immunosuppression has been reported in models of autoimmune disorders and in early-stage clinical trials, with some promising results for the treatment of graft versus host disease, multiple sclerosis, systemic lupus erythematosus and other conditions. But this is the first study demonstrating that multiple doses of MSCs may induce immunosuppressive effects in experimental allergic asthma, Dr. Rocco said.

These findings should be borne in mind for future clinical trials in patients with severe asthma.

Outcomes from this study highlight the potential of mesenchymal stromal cells to reduce lung inflammation caused by asthma, which affects more than 25 million people in America alone, said Anthony Atala, M.D., Editor-in-Chief of SCTM and director of the Wake Forest Institute for Regenerative Medicine. Larger clinical studies will be welcomed to further verify the safety and efficacy of this treatment.

The full article, Multiple Doses of Adipose Tissue-Derived Mesenchymal Stromal Cells Induce Immunosuppression in Experimental Asthma, can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/sctm.19-0120.

About STEM CELLS Translational Medicine: STEM CELLS Translational Medicine (SCTM), co-published by AlphaMed Press and Wiley, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices. SCTM is the official journal partner of Regenerative Medicine Foundation.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS, is the world's first journal devoted to this fast paced field of research. The Oncologist (http://www.TheOncologist.com), also a monthly peer-reviewed publication, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.

About Regenerative Medicine Foundation (RMF): The non-profit Regenerative Medicine Foundation fosters strategic collaborations to accelerate the development of regenerative medicine to improve health and deliver cures. RMF pursues its mission by producing its flagship World Stem Cell Summit, honouring leaders through the Stem Cell and Regenerative Medicine Action Awards, and promoting educational initiatives.

Share article on social media or email:

Read more here:
Multiple Doses of Stem Cells Show Potential in Treating Severe Asthma - PR Web

Full Alliance Group Announces New EBO2 Sites in Florida and the Caribbean – P&T Community

BEVERLY HILLS, California, Nov. 21, 2019 /PRNewswire/ -- Full Alliance Group, Inc. (OTCPK: FAGI) is pleased to announce the opening of two new EBO2 treatment offices.

Dr. Yu and his staff arrived in Boca Raton, Florida, and then the Cayman Islands earlier this week with two brand-new portable EBO2 units and are currently training Dr. Joseph Purita and his staff. Dr. Purita is well-known in the stem cell and regenerative medicine sector and is eager to implement our ozone technology within his thriving practice.He has offices in Boca Raton as well as in the Cayman Islands.

Dr. Purita's Pensum Regenerative Clinic in Grand Cayman already specializes in stem cell treatment and anti-aging.The addition of EBO2 technology is expected to work synergistically with the well-established stem cell protocols already in place at the clinic.

"Expanding our footprint to the East and South, as well as the Caribbean, has been a critical part of our strategic plan," said Dr. Brian Volpp, MD, CEO and President of Full Alliance Group, Inc. "We are grateful that Dr. Purita has committed to the Yu Method and that he has made the financial commitment for two of our new units.His reputation within the stem cell community should allow ozone therapy to become more mainstream as he gains more experience with integrating EBO2 into his existing protocols."

Also, we have been advised by our legal team that the third quarter financial filing must be made publicly available to all shareholders. Consequently, the filing has been posted on our website:https://FullAlliance.com

About Full Alliance Group Inc.

Full Alliance Group Inc. (OTCPK: FAGI) is a multi-faceted holding company with various interests in technology, healthcare, and nutraceuticals. Nutra Yu, Inc., a wholly owned subsidiary of Full Alliance Group, develops, markets, and distributes a proprietary line of nutraceutical products. EBO2, Inc., a wholly owned subsidiary of Full Alliance Group, is the provider of ''EBO2'', a modern high volume blood gas exchange unit for the treatment of 5-7 liters of blood with medical ozone. The unit allows extracorporeal blood and oxygenation, ozone exposure and blood filtration.The process filters blood in a unique way by using the integrated diffusing membranes within the filter fibers to trap lipids and proteins which are in excess in the venous blood supply. The EBO2 unit is considered the world's most advanced medical ozone therapy.

For additional information regarding Full Alliance Group, visit, http://www.fullalliance.com.

Paul Brian Volpp, MD, MPH, President / CEO The Full Alliance Group

Forward-Looking StatementsThis shareholder update may contain a number of forward-looking statements. Words and variations of words such as: "expect", "goals", "could", "plans", "believe", "continue", "may", "will", and similar expressions are intended to identify our forward-looking statements, including but not limited to: our expectation for growth, benefits from brand-building, cost savings and margins. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond our control, which could cause our actual results to differ materially from those indicated in our forward-looking statements. Such factors include, but are not limited to: continued volatility of, and sharp increase in: costs/pricing actions, increased competition, ability to raise sufficient operating capital, risks from operating internationally, consumer weakness, weakness in economic conditions and tax law changes.

Full Alliance Group Inc. Investor RelationsDave DonlinEmail: Info@TheCervelleGroup.comPhone: (407) 490-6635Web: http://www.StockInvestorDaily.comVisit: http://www.fullalliance.comContact: ir@fullalliance.com

View original content:http://www.prnewswire.com/news-releases/full-alliance-group-announces-new-ebo2-sites-in-florida-and-the-caribbean-300963216.html

SOURCE Full Alliance Group, Inc.

See more here:
Full Alliance Group Announces New EBO2 Sites in Florida and the Caribbean - P&T Community

Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer | More…

DetailsCategory: More NewsPublished on Thursday, 21 November 2019 18:22Hits: 84

- Clinical and commercial agreement using MaxCytes recently launched ExPERT platform enables up to five of Vors engineered cell therapies and includes development and approval milestones and sales-based payments

- Takes MaxCytes total number of partnered commercial licenses to seven

CAMBRIDGE, MA & GAITHERSBURG, MD, USA I November 21, 2019 I Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, and MaxCyte, Inc., a global cell-based therapies and life sciences company, today announced a clinical and commercial license agreement under which Vor will use MaxCytes Flow Electroporation technology to produce eHSCs and initiate Investigational New Drug (IND)-enabling studies to accelerate its progress towards the clinic.

Under the terms of the agreement, Vor obtains non-exclusive clinical and commercial use rights to MaxCytes Flow Electroporation technology and ExPERT platform to develop up to five engineered cell therapies, including VOR33, Vors lead eHSC candidate, which is in development for acute myeloid leukemia (AML). In return, MaxCyte will receive undisclosed development and approval milestones and sales-based payments in addition to other licensing fees.

Vor will use MaxCytes cell engineering platform to deliver its gene editing machinery into hematopoietic stem cells to remove biologically redundant cell surface proteins that are also expressed on blood cancer cells. Once the eHSCs are transplanted into a cancer patient, these cells are effectively hidden from complementary targeted therapies that target the relevant protein, while diseased cells are left vulnerable to attack. Vors approach thereby could unleash the potential of targeted therapies by broadening the therapeutic window and improving the utility of complementary targeted therapies.

MaxCyte is a leader in GMP electroporation technology, and we are thrilled that this agreement provides us with long-term access to a platform technology applicable to a pipeline of eHSC programs used to treat AML and other blood cancers, said Sadik Kassim, Ph.D., Chief Technology Officer of Vor. As we build on promising in vivo data from our lead candidate VOR33, we can now expand our manufacturing capabilities to support later-stage studies, regulatory filings and commercialization of VOR33.

MaxCytes ExPERT instrument family represents the next generation of leading, clinically validated, electroporation technology for complex and scalable cellular engineering. By delivering high transfection efficiency with enhanced functionality, the ExPERT platform delivers the high-end performance essential to enable the next wave of biological and cellular therapeutics.

We look forward to expanding our relationship with Vor Biopharma as the company pioneers a potential future standard of care in hematopoietic stem cell transplants for cancer patients in need, said Doug Doerfler, President & CEO of MaxCyte. This agreement represents another key business milestone for MaxCyte, emphasizing the value of our technology platform applied to next-generation engineered cell therapies that may make a true difference in patient outcomes.

About VOR33 Vors lead product candidate, VOR33, consists of engineered hematopoietic stem cells (eHSCs) that lack the protein CD33. Once these cells are transplanted into a cancer patient, CD33 becomes a far more cancer-specific target, potentially avoiding toxicity to the normal blood and bone marrow associated with CD33-targeted therapies. In so doing, Vor aims to improve the therapeutic window and effectiveness of CD33-targeted therapies, thereby potentially broadening the clinical benefit to patients suffering from AML.

About Vor Biopharma Vor Biopharma aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies. By removing biologically redundant proteins from eHSCs, these cells become inherently invulnerable to complementary targeted therapies while tumor cells are left susceptible, thereby unleashing the potential of targeted therapies to benefit cancer patients in need.

Vors platform could be used to potentially change the treatment paradigm of both hematopoietic stem cell transplants and targeted therapies, such as antibody drug conjugates, bispecific antibodies and CAR-T cell treatments. A proof-of-concept study for Vors lead program has been published in Proceedings of the National Academy of Sciences.

Vor is based in Cambridge, Mass. and has a broad intellectual property base, including in-licenses from Columbia University, where foundational work was conducted by inventor and Vor Scientific Board Chair Siddhartha Mukherjee, MD, DPhil. Vor was founded by Dr. Mukherjee and PureTech Health and is supported by leading investors including 5AM Ventures and RA Capital Management, Johnson & Johnson Innovation JJDC, Inc. (JJDC), Novartis Institutes for BioMedical Research and Osage University Partners.

About MaxCyte MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCytes mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 80 partnered programme licenses in cell therapy with more than 45 licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit http://www.maxcyte.com.

SOURCE: MaxCyte

Link:
Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer | More...

Global Cell Separation Market 2020-2024 | Evolving Opportunities with Akadeum Life Sciences and Becton, Dickinson and Co. | Technavio – Business Wire

LONDON--(BUSINESS WIRE)--The global cell separation market is poised to grow by USD 7.12 billion during 2020-2024, progressing at a CAGR of over 17% during the forecast period. Request Free Sample Pages

Read the 142-page research report with TOC on "Cell Separation Market Analysis Report by End-User (Academic institutions and research laboratories; Pharmaceutical and biotechnology companies; and Hospitals and clinical testing laboratories), by Geography (North America, Europe, Asia, and ROW), and Segment Forecasts, 2020 - 2024"

The market is driven by the increasing use of cell separation in cancer research. In addition, the rising focus on personalized medicine is anticipated to further boost the growth of the cell separation market.

The increasing use of cell separation in cancer research will be one of the major drivers in the global market. Over the last few years, cell separation has been used along with imaging, proteomics, and molecular biological methods to identify and characterize cancer stem cells. This helps in the early diagnosis of tumors, monitoring of circulating tumor cells, and evaluation of intratumor heterogeneity. Also, the incidence of cancer is increasing rapidly, especially amongst women. Cervical and breast cancers are the most common types in the world. The rising incidence of cancer is encouraging further research in the field. Moreover, advances in computer techniques, optics, and lasers introduced a new generation of cell separation techniques which are capable of high speed processing of single cell suspensions. These factors will boost the global cell separation market growth during the forecast period of 2020-2024.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Cell Separation Market Companies:

Akadeum Life Sciences

Akadeum Life Sciences owns and operates the businesses under various segments such as T cell isolation kits, B cell isolation kits, red blood cell products, Streptavidin products, and CD45 products. The product offered by the company is human T Cell isolation kit. This product uses streptavidin-conjugated BACS microbubbles and biotinylated antibodies for cell separation.

Becton, Dickinson and Co.

Becton operates the business under three segments, which include BD medical, BD life sciences, and BD interventional. The companys key offering include the BD IMag cell separation magnet. This product is used to attract labeled cells to the adjacent walls of tubes, allowing the removal of the supernatant, which contains unlabeled cells.

Bio-Rad Laboratories Inc.

Bio-Rad Laboratories Inc. has business operations under various segments, namely life science and clinical diagnostics. The product offered by the company is the ddSEQ single-cell isolator. This product is offered as an automated device to process hundreds to tens of thousands of cells per day.

Cell Microsystems, Inc.

Cell Microsystems, Inc. operates the business under three segments, which include CellRaft AIR System, CytoSort Array, and CellRaft System for inverted microscopes. The companys key offerings include the CellRaft AIR System. This product is available with an automated precision X-Y stage and a microscope with three-channel fluorescence imaging capabilities. It is designed to reduce the time taken for cell separation.

Danaher Corp.

Danaher Corp. operates the business through the following segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions. The companys key offering in the cell separation market include Avanti J-26S XP. This product is offered as a centrifuge, which includes the elutriation particle separation functionality.

Register for a free trial today and gain instant access to 10,000+ market research reports.

Technavio's SUBSCRIPTION platform

Cell Separation End-User Outlook (Revenue, USD Million, 2020 - 2024)

Cell Separation Regional Outlook (Revenue, USD Million, 2020 - 2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on HealthCare are:

Cell Isolation Market Global Cell Isolation Market by product (consumables and instruments), end-users (AR, PB, CRO, and others), and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Go here to read the rest:
Global Cell Separation Market 2020-2024 | Evolving Opportunities with Akadeum Life Sciences and Becton, Dickinson and Co. | Technavio - Business Wire

Growing at an Annualized Rate of Over 20%, The Cell Therapy Manufacturing Market is Estimated to Reach Close to USD 10 Billion by 2030, Claims Roots…

The approval of KYMRIAH, YESCARTA, Alofisel and Zyntelgo has increased the interest of pharma stakeholders in cell therapies; further, owing to the technical challenges in this field, outsourcing manufacturing operations has become a necessity

LONDON, Nov. 21, 2019 /PRNewswire/ -- Roots Analysishas announced the addition of "Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030" report to its list of offerings.

Owing to various reasons, the demand for cell therapies is anticipated to increase over the coming years. Therefore, both therapy developers and contract service providers may need to strengthen their capabilities and expand available capacity. In this context, automation is expected to be a key enabler within the cell therapy manufacturing and contract services industry.

To order this 500+ page report, which features 160+ figures and 250+ tables, please visit this link

Key Market Insights

More than 160 organizations claim to be engaged in cell therapy manufacturing

The market landscape is dominated by industry players, representing more than 60% of the total number of stakeholders. Amongst these, over 55 are large or mid-sized firms (having more than 50 employees).

100+ players focused on T-cell and stem cell therapies

Most of these players are focused on manufacturing T-cell therapies, including CART, TCR or TILs. It is worth highlighting that more than 35 organizations claim to have necessary capabilities for the manufacturing of both types of therapies.

Presently, 70+ companies have commercial scale capacity

As majority of the cell therapy products are in clinical trials, the demand is high at this scale. However, it is worth noting that several players (~50%) have already developed commercial scale capacity for cell therapies.

Europe is currently considered a current hub for cell therapy production

More than 220 manufacturing facilities have been established by various players, worldwide; of these, 35% are in Europe, followed by those based in North America. Other emerging regions include Australia, China, Japan, Singapore, South Korea and Israel.

50+ facility expansions reported between 2015-2019

More than 85% of the expansions are related to setting up of new facilities across different regions. Maximum expansion activity was observed in the US and in certain countries within the Asia Pacific regions.

20+ companies offer automated solutions to cell therapy developers

Players that claim to offer consultancy services related to automation include (in alphabetical order) Berkeley Lights, Cesca Therapeutics, Ferrologix, FluDesign Sonics, GE Healthcare and Terumo BCT. Further, we identified players,namely (in alphabetical order) Fraunhofer Institute for Manufacturing Engineering and Automation IPA, Invetech, KMC Systems, Mayo Clinic Center for Regenerative Medicine and RoosterBio, that offer consultancy solutions related to automation.

Partnership activity has grown at an annualized rate of 16%, between 2014 and 2018

More than 200 agreements have been inked in the last 5 years; majority of these were focused on the supply of cell-based therapy products for clinical trials. Other popular types of collaboration models include manufacturing process development agreements (16%), services agreements (12%) and acquisitions (10%).

By 2030, developed geographies will capture over 60% of the market share

Asia Pacific is anticipated to capture the major share (~36%) of the market by 2030. It is also important to highlight that financial resources, technical expertise and established infrastructure is likely to drive cell therapy manufacturing market in Europe, which is estimated to grow at a CAGR of ~26%.

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

The USD 10+ billion (by 2030) financial opportunity within the cell therapy manufacturing market has been analyzed across the following segments:

The report features inputs from eminent industry stakeholders, according to whom the manufacturing of cell therapies is largely being outsourced due to exorbitant costs associated with the setting-up of in-house expertise. The report includes detailed transcripts of discussions held with the following experts:

The research covers profiles of key players (industry and non-industry) that offer manufacturing services for cell-based therapies, featuring a company overview, information on manufacturing facilities, and recent collaborations.

For additional details, please visit

https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html or email sales@rootsanalysis.com

You may also be interested in the following titles:

Contact:

Gaurav Chaudhary+1(415)800-3415Gaurav.Chaudhary@rootsanalysis.com

Logo- https://mma.prnewswire.com/media/742223/Roots_Analysis_Logo.jpg

Read more here:
Growing at an Annualized Rate of Over 20%, The Cell Therapy Manufacturing Market is Estimated to Reach Close to USD 10 Billion by 2030, Claims Roots...

WCM-Q explores law and ethics of stem cells and AI in medicine – Gulf Times

The legal and ethical implications of using stem cells and artificial intelligence (AI) in medicine were discussed at the latest instalment of Weill Cornell Medicine Qatars (WCM-Q) Intersection of Law & Medicine series.Expert speakers at the event discussed the impact of recent advances in stem cell science and AI on the practice of medicine in Qatar and explored how new legal frameworks could be developed to protect the rights and safety of patients in the Mena region.The day-long event was organised by WCM-Q in collaboration with Hamad Bin Khalifa University and the University of Malaya of Kuala Lumpur, Malaysia.Stem cells are an exciting area for medical researchers because they have the potential to repair damaged or diseased tissues in people with conditions such as Parkinsons disease, type 1 diabetes, stroke, cancer, and Alzheimers disease, among many others.Stem cells can also be used by researchers to test new drugs for safety and effectiveness.Stem cells have the capacity for unlimited or prolonged self-renewal, and they can differentiate themselves into many different cell types to become tissue- or organ-specific cells with special functions, said Dr Amal Robay, WCM-Q assistant professor in genetic medicine and director of research compliance.The central ethical dilemma of stem cell science arises from the fact that embryonic stem cells are derived from human embryos or by cloning, she explained.Visiting bioethics expert Dr Jeremy Sugarman of Johns Hopkins University in Baltimore, US said that the public image of stem cell research had been damaged by a small number of high-profile cases in which scientists had behaved unethically.The field had also been hampered by different countries applying different laws to stem cell research, making international collaboration problematic, he said.Meanwhile, the use of AI in healthcare has the potential to leverage analysis of large amounts of data to improve patient outcomes, but poses ethical concerns regarding privacy, the diversity of data sources, biases and relying on non-human entities for potentially life-changing decisions.Its very important that we bridge that gap between the professions of law and medicine, and that we understand the fundamental importance of ethicists to the advance of science, said Dr Barry Solaiman, assistant professor of law in the College of Law and Public Policy at HBKU .We need to consider how lawyers can help to develop laws to ensure that science advances and that it does so in ways that protect everyone involved.The event, which was co-directed by Dr Solaiman and Dr Thurayya Arayssi, professor of clinical medicine and senior associate dean for medical education and continuing professional development at WCM-Q, also featured other expert speakers.Dr Mohamed Firdaus bin Abdul Aziz of the Faculty of Law at the University of Malaya, who spoke about stem cell regulations around the world, Dr Faisal Farooq of Qatar Computing Research Institute, who spoke about AI in healthcare, Dr Effy Vayena of the Swiss Institute of Technology on the ethical challenges of using machine learning in healthcare, Dr Sharon Kaur of the Faculty of Law at the University of Malaya on global regulation of AI, and Dr Mohamed Ghaly of Qatar Faculty of Islamic Studies on Islamic perspectives of bioethics in stem cell research.The visiting experts also engaged in two panel discussions, one examining the law and ethics of stem cell science, chaired by Dr Adeeba Kamarulzaman, dean of medicine at the University of Malaya, and one on AI in healthcare chaired by Dr Thurayya Arayssi, professor of clinical medicine and senior associate dean for medical education and continuing professional development at WCM-Q.

Read more:
WCM-Q explores law and ethics of stem cells and AI in medicine - Gulf Times